Cambridge Healthtech Institute’s 4th Annual
Adoptive T-Cell Therapy
Effective and Unconventional Strategies
21-22 March 2019
The therapeutic potential of adoptive T-cell therapy was first acknowledged a couple decades ago, but it was only last year that we transformed adoptive T-cell therapy into a viable therapeutic option for patients by the two CAR T-cell therapies approved by the FDA. Although this is a very exciting time for adoptive T-cell therapy, there is still much to be done to reach its full potential. Cambridge Healthtech Institute’s 4th Annual Adoptive T-Cell Therapy will gather experts in the field to address clinical progress, discuss strategies to reduce toxicity, increase efficacy, production and cost-effectiveness, along with showcasing emerging unconventional T-cell therapies.
Preliminary Agenda
NK Fighter CAR T Cells
Mark Exley, Vice President, Cellular Immunology, Agenus
New Horizons for Adoptive T Cell Therapy
Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre, Australia
TCR-Engineered T Cells Combined with T Cell Co-Stimulation to Treat Solid Tumors
Reno Debets, PhD, Associate Professor, Laboratory of Tumor Immunology, PI, Medical Oncology Erasmus MC Cancer Institute
Preclinical Data and Clinical Plan for Developing Tumour Infiltrating Lymphocytes (TIL) for Solid Tumor Indication
Robert Hawkins, MB BS, MRCP, PhD, FRCP, Cancer Research UK Professor, Medical Oncology, University of Manchester & Honorary Consultant, Medical Oncology, Christie Hospital
First Allogeneic CAR T-Cell Therapy Trial/ CYAD 101
David Gilham, Vice President Research and Development, Celyad
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
Hinrich Abken, MD, PhD, Professor, Cancer Genetics and Immunology, University of Cologne
Targeting Cytokines to the Tumor Vasculature to Improve Therapeutic Efficacy of Adoptive T Cell Therapy
Anna Mondino, Head, Lymphocyte Activation Unit, Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute
PANEL DISCUSSION: Safety Management of Cytokine release and Toxicity
Moderator: Michaela Sharpe, PhD, Head of Nonclinical Safety and Immunotherapy Strategy, Cell and Gene Therapy Catapult
UK Novel and Ground-Breaking Government Investment in the Advanced Therapy Treatment Centres
Jacqueline Barry, PhD, Chief Clinical Officer, Cell and Gene Therapy Catapult
For more details on the conference, please contact:
Emily Le
Conference Producer
Cambridge Healthtech Institute
Phone: (+1) 781-247-1812
Email: ele@healthtech.com
For partnering and sponsorship information, please contact:
Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-247-6286
Email: reymael@healthtech.com